APA (7th ed.) Citation

Grosicki, S., Simonova, M., Spicka, I., Pour, L., Kriachok, I., Gavriatopoulou, M., . . . Jurczyszyn, A. (2020). Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet, 396(10262), 1563. https://doi.org/10.1016/S0140-6736(20)32292-3

Chicago Style (17th ed.) Citation

Grosicki, Sebastian, et al. "Once-per-week Selinexor, Bortezomib, and Dexamethasone Versus Twice-per-week Bortezomib and Dexamethasone in Patients with Multiple Myeloma (BOSTON): A Randomised, Open-label, Phase 3 Trial." Lancet 396, no. 10262 (2020): 1563. https://doi.org/10.1016/S0140-6736(20)32292-3.

MLA (9th ed.) Citation

Grosicki, Sebastian, et al. "Once-per-week Selinexor, Bortezomib, and Dexamethasone Versus Twice-per-week Bortezomib and Dexamethasone in Patients with Multiple Myeloma (BOSTON): A Randomised, Open-label, Phase 3 Trial." Lancet, vol. 396, no. 10262, 2020, p. 1563, https://doi.org/10.1016/S0140-6736(20)32292-3.